Aspire Biopharma (NASDAQ:ASBP) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Aspire Biopharma (NASDAQ:ASBP) to a sell rating in a report released on Saturday.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Aspire Biopharma in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Sell”.

Aspire Biopharma Price Performance

ASBP opened at $2.21 on Friday. The firm has a market capitalization of $5.94 million, a price-to-earnings ratio of -4.42 and a beta of 0.81. The company’s 50 day simple moving average is $3.99 and its two-hundred day simple moving average is $11.68. Aspire Biopharma has a 1-year low of $1.65 and a 1-year high of $632.00.

Aspire Biopharma (NASDAQ:ASBP) last issued its quarterly earnings data on Friday, November 14th. The company reported ($1.60) earnings per share (EPS) for the quarter. The company had revenue of $0.00 million during the quarter.

Institutional Trading of Aspire Biopharma

Several hedge funds and other institutional investors have recently made changes to their positions in ASBP. Procyon Advisors LLC increased its holdings in Aspire Biopharma by 558.3% during the 2nd quarter. Procyon Advisors LLC now owns 648,411 shares of the company’s stock valued at $174,000 after acquiring an additional 549,911 shares in the last quarter. Crewe Advisors LLC increased its stake in shares of Aspire Biopharma by 100.0% during the 2nd quarter. Crewe Advisors LLC now owns 626,854 shares of the company’s stock worth $169,000 after purchasing an additional 313,427 shares in the last quarter. Optivise Advisory Services LLC raised its position in shares of Aspire Biopharma by 120.9% during the 2nd quarter. Optivise Advisory Services LLC now owns 235,106 shares of the company’s stock worth $63,000 after purchasing an additional 128,660 shares during the last quarter. Jane Street Group LLC lifted its stake in Aspire Biopharma by 625.8% in the 2nd quarter. Jane Street Group LLC now owns 152,552 shares of the company’s stock valued at $41,000 after buying an additional 131,533 shares in the last quarter. Finally, CIBC Bancorp USA Inc. acquired a new stake in Aspire Biopharma during the 3rd quarter valued at $28,000. Institutional investors and hedge funds own 19.17% of the company’s stock.

Aspire Biopharma Company Profile

Aspire Biopharma Inc is a specialty pharmaceutical company dedicated to developing and commercializing inhaled therapeutics for cardiopulmonary emergencies and respiratory diseases. The firm leverages proprietary formulation and drug-delivery technologies to repurpose established active pharmaceutical ingredients, aiming to enhance onset of action and improve patient convenience in acute settings. Aspire’s focus on pulmonary administration differentiates its approach from traditional oral or injectable treatments for asthma, allergic reactions, and other respiratory conditions.

The company’s lead asset is a reformulated metered-dose inhaler version of epinephrine designed to serve as an over-the-counter or prescription rescue therapy for acute bronchospasm and anaphylaxis.